MHRA Warns of Increased Risk from Overuse of Blue Inhalers

Introduction

On 24 April 2025, the MHRA highlighted concerns regarding the overuse of short-acting beta 2 agonists (SABAs), commonly known as blue inhalers, such as salbutamol and terbutaline. These inhalers are designed to provide quick relief from sudden asthma symptoms like chest tightness, wheezing, coughing, and breathlessness. However, relying solely on them without regular use of preventer inhalers can lead to worsening symptoms and an increased risk of severe asthma attacks.

MHRA’s Guidance

Dr Alison Cave, Chief Safety Officer at the MHRA, stated:

“Patient safety is our top priority and we continue to monitor all medicines to ensure their benefits outweigh any risks.

Patients should use their preventer inhaler as prescribed by their doctor, even if their asthma feels under control. Blue inhalers are important for treating symptoms during an asthma attack, but should not be used as the only treatment to manage asthma.

We advise patients to speak to a healthcare professional if they find themselves needing their blue inhaler more than twice a week. Preventer inhalers should be taken as prescribed, even when symptoms appear under control.

If asthma symptoms worsen or are not relieved by their blue inhaler, such as chest tightness, wheezing, coughing or difficulty breathing, patients should seek urgent medical help. Any suspected side effects should be reported through our Yellow Card scheme.”

Advice for Asthma Patients

Patients are advised to continue using their preventer inhaler regularly as prescribed, even when symptoms are under control. If prescribed a blue inhaler, it should be used only for managing asthma attacks and not relied upon as the sole form of treatment.

Frequent use of a blue inhaler — more than twice a week — may indicate poor asthma control, and patients in this category should consult a healthcare professional.

Those using blue inhalers without dose counters should keep track of doses manually and always have a spare available before their current inhaler runs out or expires.

Conclusion

The MHRA’s reminder reinforces the importance of using blue inhalers appropriately and prioritising preventer treatment in asthma management. Patients should follow personalised asthma action plans and consult healthcare professionals for any changes in symptoms or increased reliance on reliever inhalers.

Citation:
Medicines and Healthcare products Regulatory Agency. (2025, April 24). Patients with asthma reminded of the increased risk of severe asthma attacks from overusing blue inhalers. GOV.UK.